Rate constants for mammalian glutaredoxins and poplar GrxS12 range from 2.5 10 4 to 2 10 6 M 1 s 1 and also support a rate-limiting reductive half-reaction 19,20,21,37
Prescription semaglutide and other GLP-1 receptor agonists are regulated medicines with studied formulations, dosing, and monitoring

Compounded versions are made in pharmacy back rooms using semaglutide powder of variable origin, often with vitamin B12 or other additives marketed as "performance enhancers." A 2024 review of the legal and safety considerations around compounded injectable semaglutide flagged four recurring problems: The active ingredient often comes from non-FDA-registered foreign suppliers, with no guarantee of purity or potency Some compounded products use semaglutide salts (sodium or acetate forms) that the FDA has not approved and that haven't been studied for safety in humans Dosing errors have been common, including patients accidentally injecting 10 times the intended dose because of confusion between micrograms and milligrams Marketing claims about "personalized doses" or B12 add-ins are not supported by clinical trial data A 2025 medical news follow-up documented cases where patients receiving compounded semaglutide reported pancreatitis, hospitalizations from accidental overdoses, and lab-confirmed contamination

WASP-interacting protein family member 1 (WIPF1), a widely expressed proline-rich multidomain protein, is an oncogene that drives the aggressiveness of cancer [132, 133]
Consequently, a significant number of overweight men will need to address gynecomastia as part of their weight loss journey
But with the advent of GLP-1 weight loss medications, which are not classified as controlled substances, doctors say the prohibition is no longer needed